These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 37115491)

  • 1. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
    Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
    Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
    Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
    Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
    Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
    Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
    Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D
    Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
    Zhou X; Jiao L; Qian Y; Dong Q; Sun Y; Zheng WV; Zhao W; Zhai W; Qiu L; Wu Y; Wang H; Gao Y; Chen J
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34068552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
    Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA
    Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
    J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
    Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
    Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
    Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
    Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
    Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
    Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HDAC6 improves anti-CD47 immunotherapy.
    Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
    J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
    Zhang L; Zhao X; Niu Y; Ma X; Yuan W; Ma J
    J Extracell Vesicles; 2023 Nov; 12(11):e12379. PubMed ID: 37974395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.